At Essenlix, we are pioneering the future of health diagnostics with our groundbreaking iMOST platform. Our team, a dynamic and multidisciplinary group of experts from industry, healthcare, and academia, excels in bio-engineering, nanotechnology, advanced imaging, artificial intelligence, machine learning, and medicine.
Essenlix was founded in 2013 by Dr. Stephen Chou and Dr. Lin Chou. Stephen Chou, is a professor at Princeton University, a member of the US National Academy of Engineering, a fellow of the US National Academy of Inventors, and a serial entrepreneur.
Essenlix’s iMOST platform represents a significant leap forward in digital health technology. Designed as an industry-first, it enables individuals to conduct self-evaluations for various diseases and health-related biomarkers—including cells, proteins, small molecules, and nucleic acids—using just a tiny drop of body fluid such as blood, saliva, urine, or sweat. Our technology delivers results within minutes, anytime and anywhere, and communicates them instantly to healthcare professionals.
The iMOST platform is not only fast, user-friendly, and cost-effective, but it also ensures the accuracy and reliability of clinical lab-quality test results. This innovative system is designed to be fault-tolerant, providing dependable outcomes even when the sample, device, process, or operation is less than perfect.
Essenlix is committed to transforming traditional, cumbersome, and costly lab testing with a convenient, mobile solution, making it the cornerstone of advanced, accessible digital health monitoring.
Newsroom
-
Essenlix, Partnering with Roche Norway, Won Norway Østfold Hospital System’s “Patient At-Home Test” Innovation Partnership That Will Use Essenlix’s iMOST™ as Test Platform Nov. 16, 2021Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for both personal and clinical use using disruptive and proprietary advanced technology, today announced that Essenlix, in partnership with Roche Norway, has won Norway Østfold Hospital System's "Patient At-Home Test" Innovation Partnership that will use Essenlix's iMOST™ as the test platform. Learn More>>
-
Medical Device Network Article May. 21, 2021Essenlix and Roche Diagnostics Norway collaborate to deploy the iMOST platform to increase patient at-home testing. Learn More>>
-
Essenlix Partners with Roche Diagnostics Norway to Employ Essenlix’s iMOSTTM Platform for Patient At-Home Test Market May. 20, 2021Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for personal, point-of-care, and clinical use using disruptive and proprietary advanced technologies, today announced that it is partnering with Roche Diagnostics Norway to implement Essenlix’s iMOSTTM platform for the Patient At-Home Test market.
-
360Dx Article May. 20, 2021Mobile healthcare startup Essenlix announced on Thursday that it is partnering with Roche Diagnostics Norway on an initiative to increase at-home testing. Learn More>>
-
Mp.Weixin.QQ.com Article May. 20, 2021iMOST, home self-test artifact! Roche took the lead again! Learn More>>
-
Essenlix Developed the World’s Smallest, Simplest, and Lowest-Cost Blood Count Device Aug. 1, 2019With the potential to do various tests of different biomarkers in different body fluids with different biochemistries, the first application of iMOST will be iMOST-CBC. CBC or complete blood count is a vital sign of a person’s health, and one of the most common but important lab tests.
-
Business Insider Jul. 31, 2018The story might sound familiar: An entrepreneur out of a prestigious US university has developed a new blood-testing technology that can be run using only a small sample of blood. Learn More>>